An Update on Diabetes and CVD
Type 2 Diabetes: What’s new in the RACGP guidelines?
Release Date: 08/22/2021
Refreshing Key Concepts in Type 2 Diabetes
Type 2 Diabetes: What’s new in the RACGP guidelines?
Contributors to the RACGP guidelines, Dr Gary Deed (GP) and Michelle Robins (credentialled diabetes educator and nurse practitioner) along with endocrinologist Dr Tom Dover summarise why the updated guidelines were needed. Together, they consider the goals of therapy, what is meant by ‘patient-centred care’ and how it can be applied in routine clinical practice.
info_outline
What’s New in the 2020 RACGP Guidelines: Special Populations
Type 2 Diabetes: What’s new in the RACGP guidelines?
Dr Gary Deed (GP), Dr Tom Dover (endocrinologist) and Michelle Robins (CDE and nurse practitioner) discuss the key recommendations relating to some specific patient populations with type 2 diabetes, including early-onset type 2 diabetes, mental health, and the management of type 2 diabetes in older people and in aged-care facilities.
info_outline
An Update on Microvascular Complications
Type 2 Diabetes: What’s new in the RACGP guidelines?
info_outline
An Update on Diabetes and CVD
Type 2 Diabetes: What’s new in the RACGP guidelines?
Cardiovascular disease (CVD) is the leading cause of death in people with diabetes, making assessment, prevention and management of CVD risk a vital part of diabetes care.1 Dr Gary Deed (GP), Dr Tom Dover (endocrinologist) and Michelle Robins (CDE and nurse practitioner) consider the different risk assessment tools available, interventions to manage CVD risk and practical tips on approaching the multi-morbidity nature of type 2 diabetes and the application of patient-centred care.
info_outline
Mastering the Management of Type 2 Diabetes: Part 1
Type 2 Diabetes: What’s new in the RACGP guidelines?
Dr Gary Deed (GP) and Dr Tom Dover (endocrinologist) discuss the Australian type 2 diabetes management algorithm developed by the Australian Diabetes Society (ADS), dietary interventions such as high-protein and very low energy diets and pharmacotherapy considerations. Michelle Robins (CDE and nurse practitioner) highlights key educational points for people commencing on certain glucose-lowering agents.
info_outline
Mastering the Management of Type 2 Diabetes: Part 2
Type 2 Diabetes: What’s new in the RACGP guidelines?
A continuation of the previous episode, Dr Gary Deed (GP) and Dr Tom Dover (endocrinologist) continue to review the ADS type 2 diabetes treatment algorithm, with an in-depth discussion pharmacotherapy from initial therapies to considerations when selecting second-line agents and when to consider commencing insulin. Michelle Robins shares her tips and considerations on how to overcome inertia to starting insulin.
info_outlineCardiovascular disease (CVD) is the leading cause of death in people with diabetes, making assessment, prevention and management of CVD risk a vital part of diabetes care.1 Dr Gary Deed (GP), Dr Tom Dover (endocrinologist) and Michelle Robins (CDE and nurse practitioner) consider the different risk assessment tools available, interventions to manage CVD risk and practical tips on approaching the multi-morbidity nature of type 2 diabetes and the application of patient-centred care.
This podcast is intended for healthcare professionals only and should not viewed by anyone but the intended recipient. The views and opinions expressed are those of the presenters and not necessarily those of Sanofi.
References: 1. The Royal Australian College of General Practitioners. Management of type 2 diabetes: A handbook for general practice. East Melbourne, Vic: RACGP, 2020. 2. Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O.E., Woerle, H.J. and Broedl, U.C., 2015. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine, 373(22), pp.2117-2128.